Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android

Content Updates - December 2018

New Combination Agents, Biologics, and Anti-Immunoglobulin E Biologics


A wide spectrum of therapeutic agents is currently employed in the treatment of respiratory disorders, including obstructive lung diseases. This chapter reviews the rationale for, and clinical use of, these agents in current clinical practice.

Drug Delivery

Inhaled drug administration is preferred for many medical conditions. Advantages of inhaled drug administration include rapid onset of action and the ability to deliver small drug doses directly to the lungs, minimizing systemic drug exposure. Compressed air nebulizers have been in use for more than 150 years; the first metered-dose inhaler (MDI) became available in the 1950s, followed by the first dry powder inhaler (DPI) in the 1960s.1 Many new and innovative devices have been marketed as the result of the phase-out of chlorofluorocarbon-containing MDIs.2

Device selection depends on drug–device availability, patient characteristics (e.g., age, cognitive function, manual dexterity), and patient preference (Tables 145-1 and 145-2).3,4 MDIs and nebulizers share universal designs; other drug delivery devices are unique, individually patented devices.

Table 145-1Inhaled Drug–Device Availability
Table 145-2Age–Device Guidelines

MDIs are small portable ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.